Last updated: about 1 month ago
AstraZeneca's Imfinzi Breaks Ground in MIBC Treatment: SEC Report Insights
Discover AstraZeneca's groundbreaking approval of Imfinzi for muscle-invasive bladder cancer, backed by clinical trials showing improved survival rates and reduced recurrence.